IBT
International Biotechnology Trust Portfolio holdings
AUM
$297M
This Quarter Return
+15.42%
1 Year Return
+17.25%
3 Year Return
+11.14%
5 Year Return
+79.35%
10 Year Return
–
AUM
$324M
AUM Growth
+$324M
(+3.8%)
Cap. Flow
-$25M
Cap. Flow
% of AUM
-7.72%
Top 10 Holdings %
Top 10 Hldgs %
51.2%
Holding
69
New
3
Increased
9
Reduced
7
Closed
6
Top Buys
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$4.89M |
| 2 |
PTC Therapeutics
PTCT
|
$4.69M |
| 3 |
AstraZeneca
AZN
|
$4.41M |
| 4 |
Illumina
ILMN
|
$4.34M |
| 5 |
Travere Therapeutics
TVTX
|
$4.05M |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$15.9M |
| 2 |
Gilead Sciences
GILD
|
$13M |
| 3 |
Biogen
BIIB
|
$6.67M |
| 4 |
Galapagos
GLPG
|
$5.25M |
| 5 |
Incyte
INCY
|
$4.82M |
Sector Composition
| 1 | Healthcare | 99.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $35.8M | 11.07% | 314,973 -140,000 | -31% | -$15.9M |
|
|
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
| $21.4M | 6.6% | 166,200 | – | – |
|
|
3
Incyte
INCY
$16.5B
| $18.4M | 5.68% | 229,000 -60,000 | -21% | -$4.82M |
|
4
Alkermes
ALKS
$4.78B
| $15.5M | 4.78% | 593,000 | – | – |
|
5
Harmony Biosciences
HRMY
$2.12B
| $14.6M | 4.5% | 264,500 | – | – |
|
6
uniQure
QURE
$896M
| $14.3M | 4.42% | 631,500 +87,000 | +16% | +$1.97M |
|
7
Supernus Pharmaceuticals
SUPN
$2.53B
| $13.7M | 4.22% | 383,500 +86,000 | +29% | +$3.07M |
|
|
ITCI
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $11.7M | 3.62% | 221,856 | – | – |
|
|
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $11.1M | 3.41% | 244,000 +108,000 | +79% | +$4.89M |
|
|
10
Illumina
ILMN
$15.8B
| $9.4M | 2.9% | 46,500 +21,500 | +86% | +$4.34M |
|
11
Alnylam Pharmaceuticals
ALNY
$58.5B
| $9.02M | 2.79% | 38,000 | – | – |
|
|
KDNY
12
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $8.91M | 2.75% | 340,389 | – | – |
|
13
Exelixis
EXEL
$10.1B
| $8.71M | 2.69% | 543,000 | – | – |
|
14
Regeneron Pharmaceuticals
REGN
$61.5B
| $8.08M | 2.5% | 11,200 | – | – |
|
15
Ultragenyx Pharmaceutical
RARE
$2.89B
| $8.06M | 2.49% | 174,052 | – | – |
|
|
16
Travere Therapeutics
TVTX
$1.56B
| $7.96M | 2.46% | 379,019 +193,000 | +104% | +$4.05M |
|
17
Dyne Therapeutics
DYN
$1.92B
| $7.42M | 2.29% | 641,068 +291,000 | +83% | +$3.37M |
|
18
Sanofi
SNY
$121B
| $6.94M | 2.14% | 143,500 | – | – |
|
|
19
Biogen
BIIB
$19.4B
| $5.92M | 1.83% | 21,400 -24,100 | -53% | -$6.67M |
|
|
20
PTC Therapeutics
PTCT
$3.92B
| $5.49M | 1.7% | 144,000 +123,000 | +586% | +$4.69M |
|
21
Vera Therapeutics
VERA
$1.38B
| $5.43M | 1.68% | 281,257 | – | – |
|
|
22
Gilead Sciences
GILD
$140B
| $4.94M | 1.53% | 57,584 -151,200 | -72% | -$13M |
|
23
BioMarin Pharmaceuticals
BMRN
$11.2B
| $4.51M | 1.39% | 43,656 -15,000 | -26% | -$1.55M |
|
|
24
AstraZeneca
AZN
$248B
| $4.41M | 1.36% | +65,000 | New | +$4.41M |
|
25
Amgen
AMGN
$155B
| $4.27M | 1.32% | 16,246 | – | – |
|